Experiments
Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).
-
Full-text index only
25th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, USA, 10-14 December 2002 Update on preclinical and translational research.
PMID 12631391 · PMC154153 · Breast cancer research : BCR · 2003 · 8 claims · 8 setups
Growth factor signalling (EGF/HER-2/MAPK, AKT) phosphorylates the oestrogen receptor and drives development of endocrine-resistant breast cancer
-
Full-text index only
Leveraging the germ layer development patterns to predict prognosis and identify MEST as a novel therapeutic target in glioma.
PMID 41501725 · PMC12870398 · Cancer cell international · 2026 · 7 claims · 8 setups
MEST is a key oncogenic GLD-related gene and a novel therapeutic target in glioma, identified via a machine learning feature selection framework
-
Has reproduction · 63
Stromal androgen signaling acts as tumor niches to drive prostatic basal epithelial progenitor-initiated oncogenesis.
PMID 36323713 · PMC9630272 · Nature communications · 2022 · 8 claims · 8 setups
Loss of AR in stromal Gli1-lineage cells diminishes prostate epithelial oncogenesis and tumor development in vivo
-
Full-text index only
Identification of Molecular Subtypes of Clear-Cell Renal Cell Carcinoma in Patient-Derived Xenografts Using Multi-Omics.
PMID 40282537 · PMC12026142 · Cancers · 2025 · 8 claims · 7 setups
Each ccRCC PDX resembles one of the human molecular subtypes closely at both the transcript and protein levels.
-
Full-text index only
Single-Cell Lineage Tracing Uncovers Resistance Signatures and Sensitizing Strategies to FLT3 Inhibitors in Acute Myeloid Leukemia.
PMID 41270153 · PMC7618455 · Cancer research · 2026 · 8 claims · 8 setups
ReSisTrace single-cell lineage tracing identifies pre-resistant and pre-sensitive cell states to FLT3 inhibitors midostaurin and quizartinib in FLT3-ITD-positive MOLM-13 AML cells before treatment